Revenue Update on AEterna Zentaris (USA)(NASDAQ:AEZS)

AEterna Zentaris (USA)(NASDAQ:AEZS) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 15, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-0.71.

AEterna Zentaris (USA) (AEZS) made into the market gainers list on Fridays trading session with the shares advancing 1.69% or 0.05 points. Due to strong positive momentum, the stock ended at $3, which is also near the day’s high of $3. The stock began the session at $2.95 and the volume stood at 59,012 shares. The 52-week high of the shares is $5.59 and the 52 week low is $2.35. The company has a current market capitalization of $40 M and it has 1,34,73,063 shares in outstanding.

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology endocrinology and women’s health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH based in Frankfurt Germany Zentaris IVF GmbH a direct wholly owned subsidiary of AEZS Germany based in Frankfurt Germany and Aeterna Zentaris Inc. Its drug development efforts are focused on two compounds zoptarelin doxorubicin and Macrilen which are in clinical development and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates) which are in pre-clinical development. Zoptarelin doxorubicin represents a hybrid molecule composed of a synthetic peptide carrier and a chemotherapy agent doxorubicin. Macrilen (macimorelin acetate) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor.

Add Comment